Filing Flows › Guardant Health (GH) › Guidance history
Guardant Health (GH) guidance history: what it guided and what it reported
Guardant Health gave guidance in 12 earnings releases on file since Feb 22, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +1.9% against the guided midpoint. Its releases raised guidance 9 times and lowered it once.
Revenue
Met or beat 2 of 2 periods (2 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.2B–$1.3B (Feb 19, 2026) → raised $1.3B–$1.3B (May 7, 2026) → raised $1.3B–$1.4B (Jul 30, 2026) → raised $1.4B–$1.4B (Nov 5, 2026) | — | to be reported | — |
| FY2025 | $850M–$860M (Feb 20, 2025) → raised $880M–$890M (Apr 30, 2025) → raised $915M–$925M (Jul 30, 2025) → raised $965M–$970M (Oct 29, 2025) | $982M | above the range | +1.5% |
| FY2024 | $675M–$685M (May 9, 2024) → raised $690M–$700M (Aug 7, 2024) → raised $720M–$725M (Nov 6, 2024) | $739M | above the range | +2.3% |
Adjusted gross margin
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 64.0%–65.0% (Feb 19, 2026) → reaffirmed 64.0%–65.0% (May 7, 2026) → reaffirmed 64.0%–65.0% (Jul 30, 2026) → raised 65.0% (Nov 5, 2026) | — | to be reported | — |
| FY2025 | 62.0%–63.0% (Feb 20, 2025) → reaffirmed 62.0%–63.0% (Apr 30, 2025) → raised 63.0%–64.0% (Jul 30, 2025) → raised 64.0%–65.0% (Oct 29, 2025) | — | — | — |
| FY2024 | 60.0%–62.0% (Feb 22, 2024) → raised 61.0%–63.0% (May 9, 2024) → reaffirmed 61.0%–63.0% (Aug 7, 2024) → reaffirmed 61.0%–63.0% (Nov 6, 2024) | — | — | — |
Adjusted operating expenses
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.0B–$1.1B (Feb 19, 2026) → raised $1.1B–$1.1B (May 7, 2026) → raised $1.1B–$1.1B (Jul 30, 2026) → raised $1.1B–$1.1B (Nov 5, 2026) | — | to be reported | — |
| FY2025 | $815M–$825M (Feb 20, 2025) → raised $830M–$840M (Apr 30, 2025) → raised $840M–$850M (Jul 30, 2025) → raised $865M–$875M (Oct 29, 2025) | — | — | — |
| FY2024 | $740M–$750M (Feb 22, 2024) → lowered $720M–$730M (May 9, 2024) → reaffirmed $720M–$730M (Aug 7, 2024) → reaffirmed $720M–$730M (Nov 6, 2024) | — | — | — |
Free cash flow
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $185M–$195M (May 7, 2026) → raised $195M–$205M (Jul 30, 2026) → raised $205M–$220M (Nov 5, 2026) | — | to be reported | — |
| FY2025 | $225M–$235M (Feb 20, 2025) → reaffirmed $225M–$235M (Apr 30, 2025) → reaffirmed $225M–$235M (Jul 30, 2025) → reaffirmed $225M–$235M (Oct 29, 2025) | — | — | — |
| FY2024 | $320M–$330M (Feb 22, 2024) → lowered −$285M–−$275M (May 9, 2024) → reaffirmed −$285M–−$275M (Aug 7, 2024) → raised −$275M–−$265M (Nov 6, 2024) | — | — | — |
The latest quarter
Guardant Health, Q3 2026: revenue $361M (+36% year over year), operating margin -36.8%, net loss $124M, operating cash flow −$23.7M. The chart follows the revenue to costs, profit and cash.
Questions
Does Guardant Health beat its guidance?
Guardant Health gave guidance in 12 earnings releases on file since Feb 22, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +1.9% against the guided midpoint.
How often does Guardant Health raise guidance?
Its earnings releases raised guidance 9 times and lowered it once since Feb 22, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.